MetLife Q2 Earnings Lag Estimates on Soft MetLife Holdings Unit

MetLife (MET) reported Q2 2025 adjusted EPS of $2.02, missing estimates by 7.8% and declining 11% year-over-year, alongside a 4.1% revenue drop to $17.9 billion. This underperformance largely stemmed from weakness in Asia, Group Benefits, RIS, and MetLife Holdings, attributed to factors like lower underwriting results and less favorable investments, despite strong offsetting growth in Latin America and EMEA. While the company maintains near-term targets including double-digit adjusted EPS growth and over $25 billion in free cash flow, the current results and a Zacks Rank #4 (Sell) indicate immediate challenges.

Analysis

MetLife reported a challenging second quarter for 2025, with adjusted operating EPS of $2.02 missing consensus estimates by 7.8% and declining 11% year-over-year. The top line also disappointed, with adjusted revenues falling 4.1% to $17.9 billion. This underperformance was primarily driven by broad-based weakness across its largest segments, including a 25% earnings decline in Group Benefits, a 22% drop in Asia, and a 10% decrease in Retirement and Income Solutions (RIS), all attributed to softer underwriting results and less favorable investment income. While strong results in the smaller EMEA and Latin America segments, which saw earnings grow 30% and 3% respectively, provided a partial offset, they were insufficient to overcome the headwinds in core businesses. Key profitability metrics also deteriorated, with net income falling 23% and the adjusted return on equity contracting 270 basis points to 14.6%. Despite these results, the company displayed operational discipline with a 1.6% decline in total expenses and maintained a robust capital return program, executing a $510 million share buyback. A significant disconnect exists between the current poor performance and management's maintained ambitious near-term targets, which include double-digit EPS growth and an adjusted ROE of 15-17%.

Key Decisions for Investors

• Investors should closely monitor the performance of the Asia, Group Benefits, and RIS segments in subsequent quarters, as a turnaround is critical for the company to meet its ambitious double-digit EPS growth guidance.
• The significant gap between the reported Q2 adjusted ROE of 14.6% and the company's 15-17% target represents a key risk, suggesting potential for a downward guidance revision if underwriting and investment results do not materially improve.
• While the aggressive capital return program provides valuation support, the reported Zacks Rank #4 (Sell) and fundamental weakness in core operations warrant caution, and investors may consider waiting for a clear inflection point before increasing exposure.